Correlation Between Higher Cumulative Dose of Cisplatin for Concurrent Chemoradiation and Acute Kidney Disease Incidence Among Nasopharyngeal Carcinoma Patients: A Comparative Study

References

• Kentjono WA. Perkembangan terkini penatalaksanaan karsinoma nasofaring (Current updates on the treatment of nasopharyngeal carcinoma). Maj Kedokteran Trop Indones; 2003.
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Fles R, Wildeman MA, Sulistiono B, Haryana SM, Tan IB. Knowledge of general practitioners about nasopharyngeal cancer at the Puskesmas in Yogyakarta, Indonesia. BMC Med Educ. 2010;10. doi:10.1186/1472-6920-10-81
   PubMed Web of Science ®Google Scholar
• Dasari S, Bernard Tchounwou P. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
   PubMed Web of Science ®Google Scholar
• Reiss KA, Hilary Calvert A, O’Dwyer PJ. Platinum analogs. In: Devita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. Lippincott Williams & Wilkins; 2018.
   Google Scholar
• Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310–1317. doi:10.1200/JCO.1998.16.4.1310
   PubMed Web of Science ®Google Scholar
• Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631–637. doi:10.1200/JCO.2003.06.158
   PubMed Web of Science ®Google Scholar
• Chan ATC, Leung SF, Ngan RKC, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97(7):536–539. doi:10.1093/jnci/dji084
   PubMed Web of Science ®Google Scholar
• Loong HH, Ma BBY, Leung SF, et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):300–304. doi:10.1016/j.radonc.2011.12.022
   PubMed Web of Science ®Google Scholar
• Lv JW, Qi ZY, Zhou GQ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Sci. 2018;109(3):751–763. doi:10.1111/cas.13474
   PubMed Web of Science ®Google Scholar
• Peng H, Chen L, Zhang Y, et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a prospective Phase III Clinical Trial. Oncologist. 2016;21(11):1369–1376. doi:10.1634/theoncologist.2016-0105
   PubMed Web of Science ®Google Scholar
• Danchaivijitr P, Ngamphaiboon N, Jiarpinitnun C, Sirachainan E, Pattaranutaporn P, Setakornnukul J. An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective multicenter study. Ann Oncol. 2016;27(Supplement 6):vi344. doi:10.1093/annonc/mdw376.50
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines Version 2.2020 head and neck cancers. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®); 2020.
   Google Scholar
• Dabholkar M, Bostick-bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst. 1992;84(19):1512–1517. doi:10.1093/jnci/84.19.1512
   PubMedGoogle Scholar
• Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3:1351–1371. doi:10.3390/cancers3011351
   PubMedGoogle Scholar
• Vincent IS, Okusa MD. Biology of renal recovery: molecules, mechanisms, and pathways. Nephron Clin Pract. 2014;127:10–14. doi:10.1159/000363714
   PubMedGoogle Scholar
• Driessen CML, Uijen MJM, Van Der Graaf WTA, et al. Degree of nephrotoxicity after intermediate- or high-dose cisplatin-based chemoradiotherapy in patients with locally advanced head and neck cancer. Head Neck. 2016;38:E1575–E1581. doi:10.1002/hed.24281
   PubMed Web of Science ®Google Scholar
• Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11:1173–1179. doi:10.2215/CJN.08070715
   PubMed Web of Science ®Google Scholar
• Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–257. doi:10.1038/nrneph.2017.2
   PubMed Web of Science ®Google Scholar
• Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347–354. doi:10.2215/CJN.03530412
   PubMed Web of Science ®Google Scholar
• Prasaja Y, Sutandyo N, Andrajati R. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia. Asian Pacific J Cancer Prev. 2015;16(3):1117–1122. doi:10.7314/APJCP.2015.16.3.1117
   PubMedGoogle Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007. doi:10.1038/sj.ki.5002786
   PubMed Web of Science ®Google Scholar
• Peres LA Lbert B, da Cunha ADA. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol ‘Orgão of Soc Bras e Latino-Americana Nefrol. 2013;35(4):332–340.
   PubMedGoogle Scholar
• Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer. 1977;39:1372–1381. doi:10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010;2(11):2490–2518. doi:10.3390/toxins2112490
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Rizzo D, Trombatore G, Maurizi P, Riccardi R. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Cancer Chemother Pharmacol. 2016;77(1):19–26. doi:10.1007/s00280-015-2913-6
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy special interest group on cancer care. Cancer Chemother Pharmacol. 2008;61:903–909. doi:10.1007/s00280-008-0711-0
   PubMed Web of Science ®Google Scholar
• Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 2015;237:219–227. doi:10.1016/j.toxlet.2015.06.012
   PubMed Web of Science ®Google Scholar
• Wei W, Huang Z, Li S, et al. Pretreatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area. Oncol Res Treat. 2014;37(3):88–95. doi:10.1159/000360178
   PubMed Web of Science ®Google Scholar
• Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43:855–866. doi:10.1007/s00134-017-4809-x
   PubMed Web of Science ®Google Scholar
• Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11(5):264–276. doi:10.1038/nrneph.2015.3
   PubMed Web of Science ®Google Scholar
• Faig J, Haughton M, Taylor RC, et al. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol Cancer Clin Trials. 2018;41:432.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N, Aspelin P, et al. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–38.
   PubMed Web of Science ®Google Scholar
• Hsu CK, Wu IW, Chen YT, et al. Acute kidney disease stage predicts outcome of patients on extracorporeal membrane oxygenation support. PLoS One. 2020;15(4):1–11. doi:10.1371/journal.pone.0231505
   Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Nainani P, Nagpal N, Agrawal M, Paliwal A. Sex hormones in gender-specific risk for head and neck cancer: a review. J Int Soc Prev Community Dent. 2014;4:1. doi:10.4103/2231-0762.144557
   PubMedGoogle Scholar
• Faiza S, Rahman S, Asri A. Karakteristik klinis dan patologis karsinoma nasofaring di bagian THT-KL RSUP Dr.M.Djamil Padang (Clinical and pathological characteristics of nasopharingeal carcinoma in the otorhinolaryngology department of Dr. M. Djamil Hospital, Padang). J Kesehat Andalas. 2016;5(1):90–96.
   Google Scholar
• Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31:185–196. doi:10.5732/cjc.011.10328
   PubMedGoogle Scholar
• Patimarattananan T, Nongnuch A, Pattaranutaporn P, Unwanatham N, Jiarpinitnun C, Ngamphaiboon N. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin. Support Care Cancer. 2021;29(2):877–887. doi:10.1007/s00520-020-05566-y
   PubMed Web of Science ®Google Scholar
• Mizushima Y, Nagahama H, Yokoyama A, Morikage T, Yano S. Studies on nephrotoxicity following a single and repeated administration of cis-Diamminedichloroplatinum (CDDP) in rats. Tohoku J Exp Med. 1987;151:129–135. doi:10.1620/tjem.151.129
   PubMed Web of Science ®Google Scholar
• Tezcan S, Izzettin FV, Sancar M, Yumuk PF, Turhal S. Nephrotoxicity evaluation in outpatients treated with cisplatin-based chemotherapy using a short hydration method. Pharmacol Pharm. 2013;04:296–302. doi:10.4236/pp.2013.43043
   Google Scholar
• Sharp CN, Siskind LJ. Developing better mouse models to study cisplatin-induced kidney injury. Am J Physiol Renal Physiol. 2017;313:F835–F841. doi:10.1152/ajprenal.00285.2017
   PubMed Web of Science ®Google Scholar
• Morgan KP, Snavely AC, Wind LS, et al. Rates of renal toxicity in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother. 2014;48(7):863–869. doi:10.1177/1060028014533303
   PubMed Web of Science ®Google Scholar
• Moon HH, Seo KW, Yoon KY, Shin YM, Choi KH, Lee SH. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011;17(30):3510-3517. doi:10.3748/wjg.v17.i30.3510
   Google Scholar
• Hrushesky WJM, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med. 1984;76:579–584. doi:10.1016/0002-9343(84)90280-8
   PubMed Web of Science ®Google Scholar
• Mizuno T, Ishikawa K, Sato W, et al. The risk factors of severe acute kidney injury induced by cisplatin. Oncol. 2013;85(6):364–369. doi:10.1159/000356587
   Google Scholar
• Loh JM, Tran AL, Ji L, et al. Baseline glomerular filtration rate and cisplatin- induced renal toxicity in urothelial cancer patients. Clin Genitourin Cancer. 2018;16(1):90–98.e1. doi:10.1016/j.clgc.2017.08.016
   Web of Science ®Google Scholar
• Andronesi AG, Tanase AD, Sorohan BM, et al. Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma. Cancer Med. 2019;8(6):3278–3285. doi:10.1002/cam4.2187
   PubMed Web of Science ®Google Scholar
• Gundog M, Basaran H, Bozkurt O, Eroglu C. A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma. Braz J Otorhinolaryngol. 2020;86(6):676–686. doi:10.1016/j.bjorl.2019.04.008
   PubMed Web of Science ®Google Scholar
• Peng H, Chen L, Li WF, et al. The cumulative cisplatin dose affects the long-term survival outcomes of patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. Sci Rep. 2016;6:1–8. doi:10.1038/s41598-016-0001-8
   PubMed Web of Science ®Google Scholar